|
Market Closed -
Nasdaq
16:00:00 2026-09-10 EDT
|
5-day change | 1st Jan Change | ||
| 57.43 USD | -1.54% |
|
-2.88% | +31.03% |
| 09-09 | Exelixis, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08:40 AM | |
| 09-09 | Adagene Receives Milestone Payment From Exelixis | MT |
Company Valuation: Exelixis, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,784 | 5,174 | 7,460 | 9,510 | 11,799 | 14,230 | - | - |
| Change | - | -10.54% | 44.19% | 27.47% | 24.07% | 20.6% | - | - |
| Enterprise Value (EV) 1 | 4,317 | 3,865 | 6,465 | 8,399 | 10,740 | 13,486 | 12,607 | 11,483 |
| Change | - | -10.45% | 67.25% | 29.91% | 27.88% | 25.56% | -6.51% | -8.92% |
| P/E | 25.4x | 28.6x | 36.9x | 18.9x | 15.8x | 17.7x | 14.7x | 11.2x |
| PBR | 2.64x | 2.09x | 3.21x | 4.18x | 5.32x | 5.47x | 4.01x | 2.98x |
| PEG | - | -1.3x | 2.3x | 0x | 0.3x | 1.1x | 0.7x | 0.4x |
| Capitalization / Revenue | 4.03x | 3.21x | 4.08x | 4.39x | 5.09x | 5.57x | 4.91x | 4.37x |
| EV / Revenue | 3.01x | 2.4x | 3.53x | 3.87x | 4.63x | 5.28x | 4.35x | 3.53x |
| EV / EBITDA | 14.4x | 17.4x | 32.9x | 13.3x | 11.9x | 12.3x | 10x | 7.2x |
| EV / EBIT | 15.1x | 19.2x | 37.8x | 13.9x | 12.3x | 13.1x | 9.87x | 7.3x |
| EV / FCF | 12.8x | 17.2x | 22.1x | 12.5x | 12.3x | 16.3x | 15.5x | 8.25x |
| FCF Yield | 7.8% | 5.8% | 4.53% | 8% | 8.15% | 6.13% | 6.44% | 12.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.72 | 0.56 | 0.65 | 1.76 | 2.78 | 3.238 | 3.914 | 5.119 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1,435 | 1,611 | 1,830 | 2,169 | 2,320 | 2,553 | 2,901 | 3,253 |
| EBITDA 1 | 300.3 | 222.4 | 196.6 | 633.4 | 901.2 | 1,093 | 1,261 | 1,595 |
| EBIT 1 | 286.7 | 201.5 | 170.9 | 604.6 | 872.2 | 1,032 | 1,278 | 1,572 |
| Net income 1 | 231.1 | 182.3 | 207.8 | 521.3 | 782.6 | 820.7 | 1,012 | 1,248 |
| Net Debt 1 | -1,467 | -1,308 | -995.3 | -1,111 | -1,059 | -744.5 | -1,623 | -2,747 |
| Reference price 2 | 18.28 | 16.04 | 23.99 | 33.30 | 43.83 | 57.43 | 57.43 | 57.43 |
| Nbr of stocks (in thousands) | 316,397 | 322,561 | 310,974 | 285,579 | 269,203 | 247,782 | - | - |
| Announcement Date | 2/17/22 | 2/7/23 | 2/6/24 | 2/11/25 | 2/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 17.74x | 5.28x | 12.34x | -.--% | 14.23B | |
| 20.07x | 7.08x | 14.22x | 1.48% | 68.24B | |
| 32.07x | 9.28x | 44.74x | 0.04% | 62.23B | |
| -77.91x | 15.04x | -72.53x | -.--% | 27.8B | |
| 28.78x | 6.1x | 15.83x | -.--% | 24.86B | |
| -14.55x | 5.23x | -6.58x | -.--% | 24.22B | |
| 26.34x | 4.96x | 16.5x | -.--% | 19.36B | |
| 49.79x | 18.37x | 37.27x | 0.3% | 17.28B | |
| 1249.7x | 36.02x | 786.01x | -.--% | 14.46B | |
| -14.53x | 3270.16x | -16.72x | -.--% | 13.56B | |
| Average | 131.75x | 337.75x | 83.11x | 0.18% | 28.62B | |
| Weighted average by Cap. | 73.58x | 164.61x | 49.79x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EXEL Stock
- Valuation Exelixis, Inc.
Select your edition
All financial news and data tailored to specific country editions
